Literature DB >> 24857840

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.

T J Hudzik1, M R Pietras2, R Caccese2, K H Bui3, F Yocca4, C A Paronis5, M D B Swedberg6.   

Abstract

AZD2327 is a brain-penetrant agonist at δ opioid receptors which has antidepressant and anxiolytic properties in a wide array of animal models. As part of the preclinical safety pharmacology assessment, a number of studies were conducted in order to characterize its behavioral effects and its potential for abuse, in order to enable testing in humans. AZD2327 produced only modest effects when tested in a multiple fixed-ratio differential reinforcement of low rate schedule in rats, and did not enhance the rate-suppressing effects of ethanol in the procedure. In a suppressed responding test, AZD2327 only reduced rates of unpunished responding. In drug discrimination studies, AZD2327 produced partial or no generalization from known drugs of abuse. In primates trained to self-administer cocaine, substitution with AZD2327 did not result in appreciable self-administration of AZD2327, indicating that it does not behave as a positive reinforcer under the present conditions. Following termination of repeated administration of AZD2327, no signs of physical dependence (withdrawal) were noted. Overall, the data suggest that AZD2327 does not possess a high potential for abuse, and appears to have only subtle behavioral effects as measured by operant behaviors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AZD2327; Abuse potential; Operant behavior

Mesh:

Substances:

Year:  2014        PMID: 24857840     DOI: 10.1016/j.pbb.2014.05.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

2.  The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.

Authors:  Shou-Pu Yi; Qing-Hong Kong; Yu-Lei Li; Chen-Ling Pan; Jie Yu; Ben-Qiang Cui; Ying-Fei Wang; Guan-Lin Wang; Pei-Lan Zhou; Li-Li Wang; Ze-Hui Gong; Rui-Bin Su; Yue-Hai Shen; Gang Yu; Kwen-Jen Chang
Journal:  Acta Pharmacol Sin       Date:  2017-05-15       Impact factor: 6.150

3.  A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.

Authors:  Erica M Richards; Daniel C Mathews; David A Luckenbaugh; Dawn F Ionescu; Rodrigo Machado-Vieira; Mark J Niciu; Wallace C Duncan; Neal M Nolan; Jose A Franco-Chaves; Thomas Hudzik; Carla Maciag; Shuang Li; Alan Cross; Mark A Smith; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

Review 4.  Hypoxic/Ischemic Inflammation, MicroRNAs and δ-Opioid Receptors: Hypoxia/Ischemia-Sensitive Versus-Insensitive Organs.

Authors:  Yimeng Chen; Yichen He; Shuchen Zhao; Xiaozhou He; Dong Xue; Ying Xia
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

5.  β-Arrestin 2 dependence of δ opioid receptor agonists is correlated with alcohol intake.

Authors:  T Chiang; K Sansuk; R M van Rijn
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

6.  Regulation of μ and δ opioid receptor functions: involvement of cyclin-dependent kinase 5.

Authors:  H Beaudry; A-A Mercier-Blais; C Delaygue; C Lavoie; J-L Parent; W Neugebauer; L Gendron
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

7.  A Novel G Protein-Biased Agonist at the δ Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain.

Authors:  Alexandra E Conibear; Junaid Asghar; Rob Hill; Graeme Henderson; Eva Borbely; Valeria Tekus; Zsuzsanna Helyes; Josephine Palandri; Chris Bailey; Ingemar Starke; Bengt von Mentzer; David Kendall; Eamonn Kelly
Journal:  J Pharmacol Exp Ther       Date:  2019-10-08       Impact factor: 4.030

8.  Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions.

Authors:  Arryn T Blaine; Yiming Miao; Jinling Yuan; Sophia Palant; Rebecca J Liu; Zhong-Yin Zhang; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.